ELDERLY PATIENT WITH TYPE 2 DIABETES MELLITUS: FOCUS ON ALOGLIPTIN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The steady increase in the proportion of the elderly population in the world and the rapidly increasing prevalence of diabetes mellitus are invariably associated with cardiovascular risks and polymorbidity. Antihyperglycemic therapy in older age groups requires an integrated and personified approach, taking into account not only the obvious advantages of intensive glycemic control, but also potential risks in the form of probable progression of cardiovascular and other concomitant pathologies, including unfavorable inter-drug interactions. This publication focuses on the possibility of use of alogliptin, a highly selective representative of the DPP-4 inhibitors, in patients of older age groups through the prism of clinical trials. This drug completely meets the abovementioned requirements and can be recommended as a reliable drug for the treatment of type 2 diabetes mellitus.

Full Text

Restricted Access

About the authors

N. A Petunina

FSBEI HE «First MSMU n.a. I.M. Sechenov» of RMH

Email: napetunina@mail.ru
MD, Prof., Head of the Department of Endocrinology IPGE Moscow

A. L Terekhova

FSBEI HE «First MSMU n.a. I.M. Sechenov» of RMH

Department of Endocrinology IPGE Moscow

References

  1. Всемирный доклад о старении и здоровье. [Электронный ресурс] Доклад ВОЗ, 2015: http://www.who.int/ageing/publications/world-report-2015/ru/
  2. World economic and social survey 2007: development in an ageing world. [Электронный ресурс] New York: United Nations; 2007: http:// www.un.org/en/development/desa/policy/wess/ wess_archive/2007wess
  3. Kim K.S., Kim S.K., Sung K.M., Cho Y.W., Park S.W. Management of type 2 diabetes mellitus in older adults. Diabetes Metab. J. 2012;36(5):336-44.
  4. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19(2):104-12.
  5. Терехова А.Л., Зилов А.В., Мельниченко Г.А., Верткин А.Л. Расхождение клинического и патологического диагнозов у полиморбидных больных с сахарным диабетом 2 типа: «цена ошибки». Проблемы эндокринологии. 2015;61(1):41-5.
  6. Терехова А.Л., Зилов А.В., Верткин А.Л., Мельниченко Г.А. Основные причины смерти и сопутствующая патология смерти у больных сахарным диабетом 2 типа по результатам аутопсий. Сахарный диабет. 2011;4:61-4.
  7. American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus., Moreno G., Mangione C.M., Kimbro L., Vaisberg E. Guidelines Abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update. J. Am. Geriatr. Soc. 2013;61(11):2020-26.
  8. American Diabetes Association. [Электронный ресурс] Standards of Medical Care in Diabetes-2017: http://professional.diabetes. org/sites/professional.diabetes.org/files/media/ dc_40_s1_final.pdf
  9. Laiteerapong N., Iveniuk J., John P.M., Laumann E.O., Huang E.S. Classification of older adults who have diabetes by comorbid conditions. United States, 2005-2006. Prev. Chronic Dis. 2012;9:E100
  10. Gregg E.W., Li Y., Wang J., Burrows N.R., Ali M.K., Rolka D., Williams D.E., Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. N. Engl. J. Med. 2014; 370:1514-23.
  11. American Diabetes Association. Standards of Medical Care in Diabetes-2015. Diabetes Care. 2015;38(Suppl. 1):1-94.
  12. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-49.
  13. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes and cardiovascular events, Diabetes Care. 2010;33(6):1389-94.
  14. Goto A., Arah O.A., Goto M., Terauchi Y., Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.
  15. Miller M.E., Bonds D.E., Gerstein H.C., Seaquist E.R., Bergenstal R.M., Calles-Escandon J., Childress R.D., Craven T.E., Cuddihy R.M., Dailey G., Feinglos M.N., Ismail-Beigi F., Largay J.F., O'Connor P.J., Paul T., Savage P.J., Schubart U.K., Sood A., Genuth S. for the ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;(340):b5444.
  16. Zoungas S., Patel A., Chalmers J., De Galan B.E., Li Q., Billot L., Woodward M., Ninomiya T., Neal B., MacMahon S., Grobbee D.E., Kengne A.P., Marre M., Heller S. Severe Hypoglycemia and Risks of Vascular Events and Death. N. Engl. J. Med. 2010;363(15):1410-18.
  17. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch. Intern. Med. 1997;157(15):1681-86.
  18. Bremer J.P., Jauch-Chara K., Hallschmid M., Schmid S., Schultes B. Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes. Diabetes Care. 2009;32(8):1513-17.
  19. Pratley R.E., McCall T., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. J. Am. Geriatr. Soc. 2009;57(11):2011-19.
  20. Committee Report: Glycemic targets for elderly patients with diabetes Japan Diabetes Society (JDS)/ Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes. J. Diabetes Investig. 2017;8(1):126-28.
  21. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. 7-й выпуск. М., 2015. 168 с.
  22. Потапова С.А., Гончарова Е.В., Петунина Н.А. Сравнительная характеристика кардиоваскулярной безопасности сахароснижающих препаратов. Лечебное дело. 2016;2:76-88.
  23. Rosenstock J., Wilson C., Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double blind, randomized, 1-year study. Diabetes Obes. Metab. 2013; 15(10):906-14.
  24. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type-2 diabetes - 2008. [Электронный ресурс]: http://www. fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM071627. pdf.
  25. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.I., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F.; EXAMINE Investigators. Alogliptine after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013;369:1327-35.
  26. Christopher R., Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. Expert Rev. Clin. Pharmacol. 2009;2(6):589-600.
  27. Andukuri R., Drincic A., Rendell M. Alogliptin:a new addition to the class of DPP-4 inhibitors. Diabetes Metab. Syndr. Obes. 2009;2:117-26.
  28. Covington P., Christopher R., Davenport M., Fleck P., Mekki Q.A., Wann E.R., Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008;30(3):499-512.
  29. Jackuliak P., Payer J. Osteoporosis, Fractures, and Diabetes. Int. J. Endocrinol. 2014;2014:820615.
  30. Ma L., Oei L., Jiang L., Estrada K., Chen H., Wang Z., Yu Q., Zillikens M.C., Gao X., Rivadeneira F. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur. J. Epidemiol. 2012;27(5):319-32.
  31. Fu J., Zhu J., Hao Y., Guo C., Zhou Z. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci. Rep. 2016;6:29104.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies